Niche market Celt ACD arterial puncture closure device with PMA and CE approval targets vascular access procedures, offering a compelling value proposition for hospitals performing catheter-based interventions seeking reliable closure solutions.

Market traction Over thirty thousand patient implants in EU and USA indicate proven clinical performance and potential for expansion through speaking with large vascular surgery and interventional radiology centers, particularly where closure efficiency reduces procedure time.

Growth funding Recent equity investment and growth capital backing (approximately $7.3M) signals investor confidence and potential for sales expansion, enabling a stronger field team and strategic partnerships.

Executive access Appointment of a non-executive director with medical credentials provides a credible channel for hospital engagement, clinical endorsements, and collaboration opportunities with key opinion leaders.

Global footprint Second-generation Celt ACD deployment in the US and EU, along with a Dublin headquarters and specialized manufacturing capabilities, create a foundation for scaled distribution to US and European medical centers through partnerships or distributor networks.